The proinflammatory activity of IL-17-producing Th17 cells has been associated with the pathogenesis of several autoimmune diseases. In this article, we provide direct evidence for a role of IL-17 in the pathogenesis of systemic lupus erythematosus (SLE). The induction of SLE by pristane in IL-17-sufficient wild-type mice did not occur in IL-17-deficient mice, which were protected from development of lupus autoantibodies and glomerulonephritis. The protection from SLE in IL-17-deficient mice was associated with a reduced frequency of CD3 + CD4 2 CD8 2 double-negative T cells and an expansion of CD4 + regulatory T cells, and did not depend on Stat-1 signaling. These data affirm the key role of IL-17 in the pathogenesis of SLE and strengthen the support for IL-17 blockade in the therapy of SLE. The Journal of Immunology, 2014, 193: 540-543.
T helper 17 cells produce the proinflammatory cytokine IL-17 and are numerically expanded in several autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis (1) . In systemic lupus erythematosus (SLE), lupus mice and lupus patients have an increased production of IL-17 and an increased frequency of circulating Th17 cells that correlate with disease activity (2) (3) (4) . The increased production of IL-17 in SLE has been linked to the ability of IL-23 to promote differentiation of Th17 cells, and a reduction in lupus pathology has been observed in mice that are genetically deficient in IL-23R, or when mice were treated with anti-IL-23 Ab (5). Moreover, it has been shown that increased levels of IL-17 in SLE are associated with the expansion of IL-17-producing CD3
2 (doublenegative [DN]) T cells in peripheral blood and kidneys of SLE patients (6) and lupus-prone mice (2) . Although the findings reported above suggest a participation of IL-17 in the pathogenesis of SLE, the formal demonstration that IL-17 can promote rather than merely associate with SLE autoimmunity has yet to be provided. In other words, it needs to be known whether IL-17 is a primary driver of pathogenic events in SLE or whether it rather accompanies the chronic inflammatory process that typifies the disease (7) .
To discriminate between these two possibilities, we directly interrogated the role of IL-17 in lupus mice that were genetically deficient of this cytokine. The deficiency of IL-17 resulted in the protection from both serologic (autoantibody) and clinical (lupus nephritis) manifestations of SLE, and was associated with a reduced frequency of DN T cells and an increased frequency of Tregs. These findings strengthen support to the suggestion to block IL-17 (8), or its axis (9) , as a new therapeutic approach in SLE.
Materials and Methods

Mice
Animals were used at 8 wk of age. Wild-type (WT) C57BL/6 (B6) mice were from The Jackson Laboratory (Bar Harbor, ME), and syngeneic IL-17-deficient (IL-17 (10) . Mice were treated in conformity with federal and institutional guidelines on animal welfare, and were fed regular chow diet in a temperature-controlled room with a 12-h light/dark cycle.
Flow cytometry
Phenotypic analyses were performed with combinations of fluorochromeconjugated Ab using standard techniques. After Fc blocking, cells were labeled with FITC-, PE-, PerCP-, or allophycocyanin-conjugated antimouse Ab to CD3 (clone 17A2), CD4 (clone RM4-5), CD8 (clone 53-6.7), or CD25 (clone PC61.5) for surface staining, and to Foxp3 (clone FJK-16s) for intracellular staining, or isotype-matched control Ab (all from eBioscience, San Diego, CA). Samples were acquired on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and analyzed using FlowJo software (Tree Star, Ashland, OR).
ELISA
Serum IgG, anti-ribonucleoprotein (RNP), and anti-ssDNA Abs were measured using Alpha Diagnostic ELISA kits (San Antonio, TX), according to the manufacturer's instructions. Anti-dsDNA Ab titers were quantified by ELISA as previously described (11) . Anti-chromatin Abs were detected in sera that had been diluted 1:500, using chicken chromatin (kind gift from Dr. Minoru Satoh, University of Florida) as plate-coating Ag, and using HRP-conjugated anti-mouse IgG (Promega, Sunnyvale, CA) for detection. Serum from nephritic (NZB 3 NZW)F 1 mice served as a positive control.
Histology
Kidney sections (4 mm) were stained with H&E according to standard procedures. Assessments of pathologic changes included glomerular activity score and tubulointerstitial activity score, which were measured as described elsewhere (12) , in a blinded fashion. For indirect immunofluorescence analyses, sections were fixed in cold acetone for 5 min, washed, and blocked with 3% BSA for 1 h before staining with the following FITC-conjugated Ab: rabbit anti-mouse IgG, rabbit anti-mouse IgM, or goat anti-mouse C3 (all from Fisher Scientific, Waltham, MA). Sections were counterstained with H&E for histologic evaluation.
Statistical analyses
Statistical analyses were performed with Prism 5 software (GraphPad, San Diego, CA) using the paired t test or Mann-Whitney U test. The p values ,0.05 were considered significant.
Results
IL-17 deficiency protects mice from serologic manifestations of SLE
Total IgG, anti-ssDNA, anti-RNP, and anti-chromatin IgG levels were monitored in IL-17 2/2 and control (WT) mice after treatment with the lupus-inducing agent pristane (10) . Compared with pristane-treated WT controls that started to develop hypergammaglobulinemia and autoantibodies by 12 wk posttreatment ( Fig. 1) , pristane-treated IL-17 2/2 mice had significantly reduced titers of IgG and low anti-ssDNA, anti-nRNP, and anti-chromatin autoantibodies ( Fig. 1) . Total IgG and autoantibody levels were comparable in control groups of WT and IL 17 2/2 mice treated with vehicle ( Fig. 1) . Anti-dsDNA autoantibody levels were not measurable at any time point in IL-17 2/2 mice (with or without pristane treatment) but were detectable in WT mice at 20 wk after pristane treatment (data not shown), indicating that although induction of anti-ssDNA, anti-nRNP, and anti-chromatin autoantibodies was IL-17 dependent, the induction of anti-dsDNA Ab was not.
IL-17 deficiency prevents lupus nephritis
IL 17
2/2 mice and WT mice were sacrificed 20 wk after pristane treatment. Kidney histopathology showed that pristane-treated IL-17 2/2 mice had significantly lower renal damage than pristanetreated WT mice, as indicated by the glomerular and tubulointerstitial activity scores, and the lack of immune complexes (IgG, IgM) and C3 deposition (Fig. 2) . The findings of protection from the development of autoantibodies in IL-17 2/2 mice treated with pristane ( Fig. 1) , together with the reduced kidney pathology (Fig. 2) , suggest that IL-17 promotes not only the development of serologic manifestations of SLE, but also renal injury.
Protective effects of IL-17 deficiency do not depend on Stat1
IL-17 deficiency is associated with the suppression of the Stat1 pathway (13) . Moreover, studies in lupus mice and in lupus patients have shown that activation of Stat1 is strongly associated with SLE pathogenesis (14, 15 
/Stat1
2/2 mice that had been treated with pristane and controls that had been treated with saline (Fig. 3) . Also, no differences were observed in serum titers of total IgG, anti-ssDNA, anti-RNP, and anti-chromatin autoantibodies between IL-17 2/2 and IL-17
2/2 mice treated with pristane and saline-treated controls (Fig. 4) . Thus, the protection from SLE that is associated with IL-17 deficiency does not depend on Stat1 activity.
Protection of IL-17 2/2 mice from SLE is associated with a reduced frequency of DN T cells and an increased frequency of Tregs
Th17 cell development and effector functions are in a reciprocal relation with those of Tregs, and a fine balance between Th17 and Tregs is crucial for the maintenance of immune homeostasis (16 (Fig. 5) . The frequency of DN T cells was evaluated next, because IL-17 is also produced by DN T cells, and DN T cells are expanded in SLE (2, 6). It was found that the deficiency of IL-17 was associated with a reduced frequency of DN T cells in IL-17 2/2 mice, but not in WT controls (Fig. 5) .
Discussion
This study provides direct evidence of a promoting role for IL-17 in the pathogenesis of SLE. Although the primary physiologic role of IL-17 is to fight extracellular pathogens, increasing evidence has suggested that IL-17 can have a significant influence in the pathogenesis of several autoimmune diseases (1-4) . In SLE patients, IL-17 serum levels were increased as compared with healthy control subjects (3, 17, 18) . Moreover, MRL lpr/lpr and B6 lpr/lpr lupus mice had high levels of IL-17 (2, 5, 19) , and IL-17 could be detected in injured kidney tissues of SLE patients (6, 19) . Additional data indicated that mice lacking the IL-17R had reduced humoral responses (20) , and that mice lacking IL-17 were largely protected from the development of glomerulonephritis (21) . Although those data underscored the proinflammatory properties of IL-17 in SLE, our findings complement and expand those observations by showing that IL-17 can directly support the propathogenic events that lead to autoantibody production and kidney inflammation in SLE. In this context, we observed an IL-17 dependency of anti-ssDNA, anti-nRNP, and anti-chromatin autoantibodies (as IL-17 2/2 mice did not develop those autoantibodies), but not of anti-dsDNA Ab. These results suggested that only the production of selected patterns of autoantibodies could depend on IL-17, a finding that is consistent with the lack of a relationship between levels of IL-17 and anti-dsDNA Ab that has been reported by others (18) , and with the possibility that IL-17 might have an influence on the timing of autoantibody responses in SLE. This aspect could be interesting because, in SLE, the levels of some autoantibodies (such as anti-RNP) are relatively insensitive to disease activity, whereas others (such as antidsDNA) are produced transiently (mainly during periods of disease activity) (22, 23) .
We also found that IL-17 deficiency is associated with an expansion of Tregs (which have a protective role in SLE) (24) and a reduced frequency of DN T cells (which have a detrimental role in SLE) (2, 6) . This is important because in MRL lpr/lpr lupus mice, IL-17-producing DN T cells were expanded in peripheral lymphoid organs and infiltrated the kidneys (2), and the current new observations point to a capacity of IL-17 to directly modulate key immunoregulatory circuits in SLE.
Regarding the source of proinflammatory IL-17 after pristane administration, it appeared to include multiple immune cell populations. Indeed, in treated animals, there was a .10-fold expansion of both macrophages and neutrophils producing IL-17 in the peritoneum, in addition to a similar expansion of Th17 cells 1 wk after pristane administration (data not shown). Thus, it is likely that multiple IL-17-producing cells can act in concert to promote the proinflammatory events that culminate in the development of lupus manifestations.
In summary, this study attests a causal relation between IL-17 and the development of SLE. This link substantiates the original suggestion to block the IL-17 axis for a therapeutic management of SLE (8) . Clinical evaluation of the effects of blocking this cytokine in SLE patients is awaited. 
